Validation of major prognostic models for metastatic urothelial carcinoma using a multi-institutional cohort of the real world

Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study

Hans von der Maase, Steen Werner Hansen, J.T. Roberts et al. · Journal of Clinical Oncology · 2000 · 2.3K citations · Full text

Medicine, Oncology, Pharmacology +11

Long-Term Survival Results of a Randomized Trial Comparing Gemcitabine Plus Cisplatin, With Methotrexate, Vinblastine, Doxorubicin, Plus Cisplatin in Patients With Bladder Cancer

Hans von der Maase, Lisa Sengeløv, J.T. Roberts et al. · Journal of Clinical Oncology · 2005 · 1.9K citations

Medicine, Oncology, Urology +6

Overall <i>C</i> as a measure of discrimination in survival analysis: model specific population value and confidence interval estimation

Michael Pencina, Ralph B. D’Agostino · Statistics in Medicine · 2004 · 1.5K citations

Public Health, Biostatistics, Cardiology +12

A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study.

Patrick J. Loehrer, Lawrence H. Einhorn, Paul Elson et al. · Journal of Clinical Oncology · 1992 · 987 citations

Medicine, Oncology, Pharmacology +12

Randomized Phase II/III Trial Assessing Gemcitabine/Carboplatin and Methotrexate/Carboplatin/Vinblastine in Patients With Advanced Urothelial Cancer Who Are Unfit for Cisplatin-Based Chemotherapy: EORTC Study 30986

Maria De Santis, Joaquim Bellmunt, Graham M. Mead et al. · Journal of Clinical Oncology · 2011 · 773 citations · Full text

Medicine, Oncology, Pharmacology +13